Lenalidomide in Relapsed or Refractory Multiple Myeloma

[1]  B. Barlogie,et al.  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.

[2]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[3]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[4]  G. Morgan,et al.  Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients , 2007, British journal of haematology.

[5]  M. Dimopoulos,et al.  The evolving role of lenalidomide in the treatment of hematologic malignancies , 2007, Expert opinion on pharmacotherapy.

[6]  T. Choueiri,et al.  Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  K. Vanderkerken,et al.  Immunomodulatory drugs as a therapy for multiple myeloma. , 2006, Current pharmaceutical biotechnology.

[8]  Michael L. Wang,et al.  Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM). , 2006 .

[9]  S. Trudel,et al.  Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels. , 2006 .

[10]  Michael L. Wang,et al.  Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma. , 2006 .

[11]  L. Kmet,et al.  Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial. , 2006 .

[12]  Michael L. Wang,et al.  Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function. , 2006 .

[13]  S. Trudel,et al.  Lenalidomide (Revlimid®) +/− Corticosteroids in Elderly Patients with Relapsed/Refractory Multiple Myeloma. , 2006 .

[14]  R. Foà,et al.  Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study. , 2006 .

[15]  H. Einsele,et al.  Lenalidomide (Revlimid™), Adriamycin and Dexamethasone Chemotherapy (RAD) Is Safe and Effective in Treatment of Relapsed Multiple Myeloma - First Results of a German Multicenter Phase I/II Trial. , 2006 .

[16]  S. Jagannath,et al.  Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial. , 2006 .

[17]  G. Morgan,et al.  Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients. , 2006 .

[18]  Diane Warren,et al.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.

[19]  A. Dispenzieri,et al.  Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. , 2006, Archives of dermatology.

[20]  S. Jagannath,et al.  Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. , 2006, Blood.

[21]  John Crowley,et al.  Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. , 2006, Blood.

[22]  Shaji K. Kumar,et al.  Thalidomide and lenalidomide in the treatment of multiple myeloma. , 2006, European journal of cancer.

[23]  K. Anderson,et al.  Lenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: Clinical implications. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Zeldis,et al.  Lenalidomide and venous thrombosis in multiple myeloma. , 2006, The New England journal of medicine.

[25]  H. Goldschmidt,et al.  A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma , 2006, British journal of haematology.

[26]  Robert A Kyle,et al.  Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. , 2005, Blood.

[27]  S. Jagannath,et al.  A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma. , 2005 .

[28]  John Crowley,et al.  High Incidence of Thrombotic Events Observed in Patients Receiving Lenalidomide (L) + Dexamethasone (D) (LD) as First-Line Therapy for Multiple Myeloma (MM) without Aspirin (ASA) Prophylaxis. , 2005 .

[29]  Kenneth C Anderson,et al.  Lenalidomide and thalidomide: mechanisms of action--similarities and differences. , 2005, Seminars in hematology.

[30]  J. Miguel,et al.  The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma , 2004, Leukemia.

[31]  M. Dimopoulos,et al.  Treatment of plasma cell dyscrasias with thalidomide and its derivatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Michael L. Wang,et al.  Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. , 2003, Seminars in hematology.

[33]  A. Dalgleish,et al.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.

[34]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[35]  N. Munshi,et al.  Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. , 2002, Blood.

[36]  P. Richardson,et al.  Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications , 2001, Leukemia.

[37]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[38]  J Shaughnessy,et al.  Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. , 2001, Blood.

[39]  M. Dimopoulos,et al.  Thalidomide and dexamethasone combination for refractory multiple myeloma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  G. Morgan,et al.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. , 2001, Blood.

[41]  G Muller,et al.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.

[42]  B. Barlogie,et al.  Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.

[43]  J. Zeldis,et al.  S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. , 1999, Clinical therapeutics.

[44]  T. Schacker,et al.  Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.

[45]  B. Barlogie,et al.  Primary dexamethasone treatment of multiple myeloma. , 1992, Blood.

[46]  B. Barlogie,et al.  VAD‐based regimens as primary treatment for multiple myeloma , 1990, American journal of hematology.

[47]  B. Barlogie,et al.  High-dose glucocorticoid treatment of resistant myeloma. , 1986, Annals of internal medicine.

[48]  B. Barlogie,et al.  Effective treatment of advanced multiple myeloma refractory to alkylating agents. , 1984, The New England journal of medicine.

[49]  W. Vaughn,et al.  Melphalan therapy for plasma cell myeloma. , 1968, Blood.